Market Research Logo

Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016

Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016’, provides an overview of the Chong Kun Dang Pharmaceutical Corp’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chong Kun Dang Pharmaceutical Corp, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Chong Kun Dang Pharmaceutical Corp
  • The report provides overview of Chong Kun Dang Pharmaceutical Corp including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Chong Kun Dang Pharmaceutical Corp’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Chong Kun Dang Pharmaceutical Corp’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Chong Kun Dang Pharmaceutical Corp’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chong Kun Dang Pharmaceutical Corp
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chong Kun Dang Pharmaceutical Corp’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Chong Kun Dang Pharmaceutical Corp Snapshot
Chong Kun Dang Pharmaceutical Corp Overview
Key Facts
Chong Kun Dang Pharmaceutical Corp - Research and Development Overview
Key Therapeutic Areas
Chong Kun Dang Pharmaceutical Corp - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Chong Kun Dang Pharmaceutical Corp - Pipeline Products Glance
Chong Kun Dang Pharmaceutical Corp - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Chong Kun Dang Pharmaceutical Corp - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Chong Kun Dang Pharmaceutical Corp - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Chong Kun Dang Pharmaceutical Corp - Drug Profiles
(amlodipine besylate + candesartan cilexetil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(atorvastatin calcium + choline fenofibrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(atorvastatin calcium + ezetimibe) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(lobeglitazone + metformin hydrochloride XR) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(tadalafil + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-516 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
difelikefalin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hyaluronate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levocabastine hydrochloride + mometasone furoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nepodin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chong Kun Dang Pharmaceutical Corp - Pipeline Analysis
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Target
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Route of Administration
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Molecule Type
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action
Chong Kun Dang Pharmaceutical Corp - Dormant Projects
Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
beloranib
Chong Kun Dang Pharmaceutical Corp - Company Statement
Chong Kun Dang Pharmaceutical Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Chong Kun Dang Pharmaceutical Corp, Key Facts
Chong Kun Dang Pharmaceutical Corp - Pipeline by Indication, 2016
Chong Kun Dang Pharmaceutical Corp - Pipeline by Stage of Development, 2016
Chong Kun Dang Pharmaceutical Corp - Monotherapy Products in Pipeline, 2016
Chong Kun Dang Pharmaceutical Corp - Combination Treatment Modalities in Pipeline, 2016
Chong Kun Dang Pharmaceutical Corp - Phase III, 2016
Chong Kun Dang Pharmaceutical Corp - Phase II, 2016
Chong Kun Dang Pharmaceutical Corp - Phase I, 2016
Chong Kun Dang Pharmaceutical Corp - Preclinical, 2016
Chong Kun Dang Pharmaceutical Corp - Pipeline by Target, 2016
Chong Kun Dang Pharmaceutical Corp - Pipeline by Route of Administration, 2016
Chong Kun Dang Pharmaceutical Corp - Pipeline by Molecule Type, 2016
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action, 2016
Chong Kun Dang Pharmaceutical Corp - Dormant Developmental Projects,2016
Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products, 2016
Chong Kun Dang Pharmaceutical Corp, Other Locations
List of Figures
Chong Kun Dang Pharmaceutical Corp - Pipeline by Top 10 Indication, 2016
Chong Kun Dang Pharmaceutical Corp - Pipeline by Stage of Development, 2016
Chong Kun Dang Pharmaceutical Corp - Monotherapy Products in Pipeline, 2016
Chong Kun Dang Pharmaceutical Corp - Pipeline by Top 10 Target, 2016
Chong Kun Dang Pharmaceutical Corp - Pipeline by Route of Administration, 2016
Chong Kun Dang Pharmaceutical Corp - Pipeline by Molecule Type, 2016
Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report